LDN Social Media
Get connected with us on social networks
The role of immune modulation in cancer - Professor Angus Dalgleish (2021 Conference) (LDN, low dose naltrexone)
Dr. Angus Dalgleish, Foundation Professor of Oncology at St. George's University of London and Principal of the Institute for Cancer Vaccines and Immunotherapy, talks about low dose naltrexone and its impact on health, specifically its use in treating cancer.
LDN is bioactive and it displays anti-cancer properties, directly targeting cancer cells, and indirectly, re-educating the immune system. Dr. Dalgleish explains a major finding of his research group, that naltrexone in lower doses can inhibit tumor growth. Before Dr. Dalgleish knew much about LDN, he had a patient who had stage four melanoma and another one with widespread breast cancer metastasis. Both were both taking low dose naltrexone from Dr. Bihari in New York. He noted both of these patients were seeming to do much better than expected from conventional treatments. He became aware that this was more than just anti-tumor effects.
In one case, Dr. Dalgleish describes a 27-year-old woman with melanoma who also had severe Crohn's disease, requiring increasing steroids and anti-TNF monoclonal antibodies. The melanoma metastatic lesions increased, probably related to the immune suppressive treatment she was having for Crohn's. It was clear that unless the immune suppression was stopped, her cancer would continue to increase. And because of the link with Crohn's disease, it was decided to try low dose naltrexone. Within 48 hours she had a response so great that she was able to stop for anti-TNF treatment and reduce steroids, which then helped stabilize the melanoma.
He has observed evidence it is an immune modulator and it helps correct imbalances. Dr. Dalgleish’s theory is that LDN may be acting on other receptors than the opioid receptors, producing an “anticancer” effect. TLRs are a family of receptors that are expressed by different immune cells. Inappropriate TLR activity is associated with autoimmunity, inflammatory diseases, and cancer. This overexpressed activity is found in Crohn’s disease and in tumor types of cancer like pancreas or glioma. Data now is showing that low doses of naltrexone have a much greater impact on the TLR receptors, whereas the higher doses have a much greater impact on opiate receptors.
His several studies and subsequent case studies have shown that LDN has a direct and indirect activity on cancer. The direct effects are on cell lines in-vitro, and the indirect effects are on inflammation and antigens. LDN helps activate, boost, and restore normal immune function. It also is an antagonist for TLR receptors 7, 8, and 9 (which are particularly important in connection to cancer). At the end of his presentation, Dr. Dalgleish talks about the use of cannabinoids with LDN as a promising treatment for cancer.
KEYWORDS: low dose naltrexone, LDN, cancer, immune modulator, cannabinoids, glioma, Crohn’s Disease, cell cycle, naltrexone, anti-tumor effect, breast cancer, melanoma, Toll-like Receptor, TLR receptors